Cancer

Taglich Brothers Initiates Coverage of Cosmos Health Inc.

CHICAGO, IL / ACCESSWIRE / February 1, 2024 / Cosmos Health Inc. ("Cosmos Health" or the "Company'') (NASDAQ:COSM), a diversified,…

4 months ago

MEDITECH to Showcase What Makes Expanse the Intelligent EHR at HIMSS 2024

Visit booth #2580 to learn how Expanse’s open platform elevates the patient journey.CANTON, Mass.--(BUSINESS WIRE)--Join MEDITECH at HIMSS 2024, March…

4 months ago

New Hope For Fibromyalgia Patients: Tonix Details Results Of Second Successful Phase 3 Trial And Plans To File For FDA Approval

Fibromyalgia candidate TNX-102 SL hits primary endpoint of daily pain reduction (p=0.00005)Combination of broad-spectrum relief and favorable tolerability seen as…

4 months ago

Anti-Cancer Drugs Publishes Preclinical Data Demonstrating the Broad Antineoplastic Activity of Panavance’s Misetionamide (GP-2250)

Misetionamide showed broad antineoplastic activity in 15 different cancer types including multiple human cancer cell lines with no detrimental effect…

4 months ago

ITM Obtains Manufacturing License in the U.S.

License will support ITM’s efforts in preparing for the commercialization of its diagnostic and therapeutic radiopharmaceutical pipeline across the U.S.…

4 months ago

Century Therapeutics to Present at the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference

PHILADELPHIA, Feb. 01, 2024 (GLOBE NEWSWIRE) -- Century Therapeutics (NASDAQ: IPSC), an innovative biotechnology company developing induced pluripotent stem cell…

4 months ago

IGM Biosciences to Present at the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference

MOUNTAIN VIEW, Calif., Feb. 01, 2024 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology company creating and…

4 months ago

HUTCHMED to Announce 2023 Final Results

HONG KONG and SHANGHAI, China and FLORHAM PARK, N.J., Feb. 01, 2024 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:…

4 months ago

Launch of GIO Therapeutics, founded by Cumulus Oncology, to develop therapeutics targeting G protein-coupled receptors to treat cancer and inflammation

Launch of GIO Therapeutics, founded by Cumulus Oncology, to develop therapeutics targeting G protein-coupled receptors to treat cancer and inflammation…

4 months ago

Takeda and Protagonist Therapeutics, Inc. Enter into Worldwide License and Collaboration Agreement for Rusfertide, a Late-Stage Rare Hematology Asset

Takeda Will Be Protagonist's Co-Development, U.S. Co-Commercialization Partner With 50:50 Profit Share, and With Exclusive Ex-U.S. Global Rights to Commercialize…

4 months ago